Assessment of the Efficacy and Tolerance, and Health Economic Study of a Single Administration of Pegfilgrastim in Lymphoma or Myeloma Patients Treated With Intensive Chemotherapy and Autologous Peripheral Stem Cell Transplantation.

Trial Profile

Assessment of the Efficacy and Tolerance, and Health Economic Study of a Single Administration of Pegfilgrastim in Lymphoma or Myeloma Patients Treated With Intensive Chemotherapy and Autologous Peripheral Stem Cell Transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2013

At a glance

  • Drugs Pegfilgrastim (Primary) ; Filgrastim
  • Indications Febrile neutropenia
  • Focus Therapeutic Use
  • Acronyms PALM
  • Most Recent Events

    • 23 Feb 2013 Results of an economic analysis published in the Applied Health Economics and Health Policy.
    • 13 Jul 2011 Cost-effectiveness results presented at the 8th World Congress of the International Health Economics Association: Transforming Health and Economics.
    • 25 May 2011 Cost-effectiveness results presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top